Allan Oberman joins Concordia board
Mr. Oberman brings to Concordia more than 15 years of international pharmaceutical industry experience including his most recent role as Chief Executive Officer of specialty pharmaceutical company Sagent Pharmaceuticals, Inc.
Sagent was sold to Nichi-Iko Pharmaceutical Co. Ltd., Japan's largest generic drug manufacturer, in a transaction that closed on August 29, 2016.
Prior to Sagent, from November 2012 to December 2014, Mr. Oberman served as President and CEO of Teva Americas Generics, a region which included the U.S., Canada and Latin America.
He joined Teva in 2000 and served as President of Teva EMIA (Eastern Europe, Middle East, Israel and Africa), where he led a diverse group of countries in achieving consistent sales growth.
Mr. Oberman also served as the Chief Operating Officer of Teva International, and President and CEO of Teva Canada, formerly known as Novopharm Limited.
It is also expected that Mr. Oberman will join the Human Resources and Compensation Committee of the Board, and Mr. Jordan Kupinsky, the Corporation's lead independent director, will step down as a member of such committee. ■
LATEST MOVES FROM Ontario
- Trillium Therapeutics appoints Helen Tayton-Martin to board
- Impopharma appoints key managers
- TD Bank Group appoints Ajai Bambawale as CRO
- United Van Lines (Canada) names Dan Lawrence president
- Jamieson Wellness appoints Angela Holtham to board
More inside POST
Nomen est omen except when it's not Leadership